State Intellectual Property Office: results of clinical trials of radcivir published on April 27
-
Last Update: 2020-02-25
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
He Zhimin, deputy director of the State Intellectual Property Office, responded to the media's question that Chinese pharmaceutical companies claimed to start manufacturing readcivir generic drugs at a press conference on the joint defense and joint control mechanism of the State Council this morning He Zhimin, deputy director of the State Intellectual Property Office: at present, radcivir has not been approved for listing in any country, and it is still in the clinical stage We have officially started clinical trials of the drug in a number of hospitals in Wuhan, and the results of the clinical trials can only be published on April 27 Novel coronavirus pneumonia is very concerned about the effectiveness and safety of Reed, and we expect to see a number of drugs including Reed's new treatment for new crown pneumonia.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
